Last updated on November 2019

A Dose Escalation Study of PF 06939999 in Participants With Advanced or Metastatic Solid Tumors.


Brief description of study

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

Clinical Study Identifier: NCT03854227

Find a site near you

Start Over

Inova Schar Cancer Institute

Annandale, VA United States
4.34miles
  Connect »

Inova Schar Cancer Institute

Fairfax, VA United States
5.27miles
  Connect »